CD276 and neoplasm: These findings suggest that high-CSHRS patients may decrease anti-tumor immunity by inhibiting immune co-stimulatory signaling and promote tumor proliferation and metastasis by inhibiting T-cell activity through high expression of PVR and CD276 genes (Figure 4B).